{"id":"W2117677020","doi":"10.1056/nejmoa1112277","title":"Rivaroxaban in Patients with a Recent Acute Coronary Syndrome","year":2011,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":1887,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Janssen Pharmaceuticals; Duke Clinical Research Institute; Genentech; Eisai; Symetis; Daiichi Sankyo Europe; Sanofi; Bayer HealthCare; Amarin Corporation; Medicure; Biogen; GlaxoSmithKline; Pfizer; IC Design Education Center; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Rivaroxaban; Acute coronary syndrome; Medicine; Cardiology; Internal medicine; Intensive care medicine; Myocardial infarction; Atrial fibrillation; Warfarin","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null}